Bacil Pharma Eyes ₹50 Cr Fundraise via Multiple Modes

Bacil Pharma Limited's Board of Directors has approved a proposal to raise up to ₹50 crores through various permissible modes, including Rights Issue, Preferential Issue, or convertible securities. The board has authorized the Managing Director, CFO, and Company Secretary to explore fund-raising options, appoint intermediaries, and finalize the structure. The specific mode, size, pricing, and terms will be determined later, subject to regulatory and shareholder approvals. The meeting was held on June 26, 2026, from 4 PM to 6 PM.